Another phase 1 clinical trial of 66 BC patients with advanced HER2-positive disease investigated the administration of a plasmid DNA coding for HER2 molecule, associated with GM-CSF as an adjuvant, for 3 immunizations. This evidence concerns the gene CSF2 and breast cancer.